Best of the Blog: IN VIVO, September 2009
Executive Summary
Our favorite posts from The IN VIVO Blog about issues not covered elsewhere in this month's IN VIVO. (See the original postings for free at http://invivoblog.blogspot.com/).
You may also be interested in...
Vivus Obesity Pill Scores With Phase III Data, But Still Faces Major Market Hurdles
Qnexa combines two generics, but Vivus Chief Operating Officer Peter Tam says: "We are not concerned about generic substitution."
Vertex: Preparing to Go Commercial
With perhaps little over a year to go before it files its NDA for hepatitis C hopeful telaprevir, Vertex is gearing up for its transition to a commercially focused company. New CEO Matt Emmens talks to IN VIVO about the financial and cultural challenges of building a commercial organization to match Vertex's highly productive R&D.
Orexigen Starts Partnership Talks On Obesity Drug Contrave
Firm stresses Phase III efficacy results will pass muster with FDA.